Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 7.07%
As of Tuesday, November 17, X4 Pharmaceuticals, Inc.’s XFOR share price has surged by 7.07%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $302.3 | $212.8 | 34% |
|
| Shares Out (Mil) | 126.5 | 55.2 | 66% |
|
| Institutional Ownership | 99.1% | 93.3% | 84% |
|
| Float (Mil) | 50.7 | 40.8 | 47% |
|
| Beta | 0.47 | 1.03 | 25% |
|
| Avg Daily Volume (000s) | 887 | 559 | 68% |
|
| Price Change (52-week) |
(17.8%) | 40.3% | 38% |
|
| Growth | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 63.5% | 13.6% | 97% |
|
| Net Income (5yr) | (5.0%) | (10.5%) | 34% |
|
| EPS (5yr) | 54.2% | 15.4% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.5% | (15.7%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.190) | ($0.640) | ($0.780) | |
| Month Ago EPS | ($0.200) | ($0.668) | ($0.768) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.200) | ($0.668) | ($0.755) | |
| Year/Year Chg | 18.8% | (65.8%) | (52.9%) | |
| Financials | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $17 | $40 | 12% |
|
| Net Income (TTM) (Mil) | ($81) | ($44) | 13% |
|
| EPS (TTM) | ($0.657) | ($1.400) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($76) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $116 | $-0 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $77 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $214 | $142 | 28% |
|
| Valuation | XFOR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.14 | 1.97 | 60% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | XFOR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.8% | 67.6% | 90% |
|
| Net Margin | (474.7%) | (50.8%) | 2% |
|
| ROA | (40.7%) | (47.4%) | 13% |
|
| ROE | (80.3%) | (51.4%) | 11% |
|
| Liabilities to Assets | 40.1% | 29.6% | 31% |
|
| F-Score | 3 | 3 | 18% |
|
X4 Pharmaceuticals, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors